^
    2d
    BGB-11417-105: A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=246, Recruiting, BeOne Medicines | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • carfilzomib • pomalidomide • sonrotoclax (BGB-11417)
    4d
    A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    sonrotoclax (BGB-11417) • catadegbrutinib (BGB-16673)
    9d
    BGB-11417-105: A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=246, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • carfilzomib • pomalidomide • sonrotoclax (BGB-11417)
    11d
    BGB-11417-101: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=437, Active, not recruiting, BeOne Medicines | Trial completion date: Aug 2027 --> May 2027 | Trial primary completion date: Aug 2027 --> May 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    13d
    A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Completed, BeOne Medicines | Active, not recruiting --> Completed
    Trial completion
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    19d
    BGB-11417-303: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov)
    P3, N=630, Recruiting, BeOne Medicines
    Trial initiation date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    1m
    BGB-11417-303: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov)
    P3, N=630, Recruiting, BeOne Medicines
    Trial initiation date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    1m
    BGB-11417-304: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • sonrotoclax (BGB-11417)
    1m
    BGB-11417-204: A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, BeOne Medicines | Trial completion date: Jun 2030 --> Sep 2029 | Trial primary completion date: Oct 2027 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    2ms
    BGB-16673-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (2024-516234-35-00)
    P1/2, N=99, Recruiting, BeOne Medicines AG
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Lunsumio (mosunetuzumab-axgb) • sonrotoclax (BGB-11417) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    2ms
    BGB-11417-303CLL-RR1: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2024-517131-52-00)
    P2/3, N=285, Recruiting, BeOne Medicines AG
    New P2/3 trial
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    2ms
    ALLG NHL43: An open-label multi-centre international phase 2 trial to evaluate the safety and efficacy of two years fixed duration therapy with sonrotoclax in combination with the BGB-16673 and rituximab in patients with treatment naïve or BTKi naïve/intolerant Waldenström Macroglobulinemia (WM). (ACTRN12626000174381)
    P2, N=80, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New P2 trial
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Rituxan (rituximab) • sonrotoclax (BGB-11417) • catadegbrutinib (BGB-16673)